154 related articles for article (PubMed ID: 21612354)
1. Gender differences in the primary prevention of stroke with aspirin.
Adelman EE; Lisabeth L; Brown DL
Womens Health (Lond); 2011 May; 7(3):341-52; quiz 352-3. PubMed ID: 21612354
[TBL] [Abstract][Full Text] [Related]
2. Aspirin for primary prevention: yes or no?
Selak V; Elley CR; Wells S; Rodgers A; Sharpe N
J Prim Health Care; 2010 Jun; 2(2):92-9. PubMed ID: 20690297
[TBL] [Abstract][Full Text] [Related]
3. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.
Ridker PM; Cook NR; Lee IM; Gordon D; Gaziano JM; Manson JE; Hennekens CH; Buring JE
N Engl J Med; 2005 Mar; 352(13):1293-304. PubMed ID: 15753114
[TBL] [Abstract][Full Text] [Related]
4. Dose of aspirin in the treatment and prevention of cardiovascular disease: current and future directions.
Hennekens CH; Sechenova O; Hollar D; Serebruany VL
J Cardiovasc Pharmacol Ther; 2006 Sep; 11(3):170-6. PubMed ID: 17056829
[TBL] [Abstract][Full Text] [Related]
5. Gender and stroke: acute phase treatment and prevention.
Sacco S; Cerone D; Carolei A
Funct Neurol; 2009; 24(1):45-52. PubMed ID: 19403054
[TBL] [Abstract][Full Text] [Related]
6. Aspirin therapy and primary prevention of cardiovascular disease in diabetes mellitus.
Younis N; Williams S; Soran H
Diabetes Obes Metab; 2009 Nov; 11(11):997-1000. PubMed ID: 19531055
[TBL] [Abstract][Full Text] [Related]
7. Low-dose aspirin for primary prevention of cardiovascular disease.
Bredie SJ; Wollersheim H; Verheugt FW; Thien T
Semin Vasc Med; 2003 May; 3(2):177-84. PubMed ID: 15199480
[TBL] [Abstract][Full Text] [Related]
8. Ischemic stroke in patients receiving aspirin.
Pujol Lereis VA; Ameriso S; Povedano GP; Ameriso SF
J Stroke Cerebrovasc Dis; 2012 Nov; 21(8):868-72. PubMed ID: 21703876
[TBL] [Abstract][Full Text] [Related]
9. FPIN's clinical inquiries. Aspirin in patients with acute ischemic stroke.
Park MK; Smith PC; Wanserski G; Neher JO
Am Fam Physician; 2009 Feb; 79(3):226-7. PubMed ID: 19202970
[No Abstract] [Full Text] [Related]
10. [Primary prevention of cardiovascular diseases with acetylsalicylic acid].
Waltering A; Hemkens L; Florack C
Dtsch Med Wochenschr; 2005 Dec; 130(49):2847-52. PubMed ID: 16317615
[TBL] [Abstract][Full Text] [Related]
11. Aspirin for primary prevention of cardiovascular disease in diabetes mellitus.
Pignone M; Williams CD
Nat Rev Endocrinol; 2010 Nov; 6(11):619-28. PubMed ID: 20856266
[TBL] [Abstract][Full Text] [Related]
12. Aspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-analysis.
Zhang C; Sun A; Zhang P; Wu C; Zhang S; Fu M; Wang K; Zou Y; Ge J
Diabetes Res Clin Pract; 2010 Feb; 87(2):211-8. PubMed ID: 19853947
[TBL] [Abstract][Full Text] [Related]
13. Update on aspirin in the treatment and prevention of cardiovascular disease.
Hennekens CH
Am J Manag Care; 2002 Dec; 8(22 Suppl):S691-700. PubMed ID: 12512736
[TBL] [Abstract][Full Text] [Related]
14. The need for wider and appropriate utilization of aspirin and statins in the treatment and prevention of cardiovascular disease.
Hennekens CH; Schneider WR
Expert Rev Cardiovasc Ther; 2008 Jan; 6(1):95-107. PubMed ID: 18095910
[TBL] [Abstract][Full Text] [Related]
15. Low-dose aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis.
Stavrakis S; Stoner JA; Azar M; Wayangankar S; Thadani U
Am J Med Sci; 2011 Jan; 341(1):1-9. PubMed ID: 21191260
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk.
Greving JP; Buskens E; Koffijberg H; Algra A
Circulation; 2008 Jun; 117(22):2875-83. PubMed ID: 18506010
[TBL] [Abstract][Full Text] [Related]
17. Antithrombotic agents in the prevention of ischemic stroke.
Bousser MG
Cerebrovasc Dis; 2009; 27 Suppl 3():12-9. PubMed ID: 19439936
[TBL] [Abstract][Full Text] [Related]
18. Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses.
Hennekens CH; Sacks FM; Tonkin A; Jukema JW; Byington RP; Pitt B; Berry DA; Berry SM; Ford NF; Walker AJ; Natarajan K; Sheng-Lin C; Fiedorek FT; Belder R
Arch Intern Med; 2004 Jan; 164(1):40-4. PubMed ID: 14718320
[TBL] [Abstract][Full Text] [Related]
19. Systematic reporting bias in meta-analyses of trials of aspirin for the primary prevention of cardiovascular disease.
Cleland JG
Am J Med; 2012 Feb; 125(2):e13. PubMed ID: 22269629
[No Abstract] [Full Text] [Related]
20. Aspirin for the primary prevention of cardiovascular events: a systematic review and meta-analysis comparing patients with and without diabetes.
Calvin AD; Aggarwal NR; Murad MH; Shi Q; Elamin MB; Geske JB; Fernandez-Balsells MM; Albuquerque FN; Lampropulos JF; Erwin PJ; Smith SA; Montori VM
Diabetes Care; 2009 Dec; 32(12):2300-6. PubMed ID: 19741185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
